Johnson & Johnson (JNJ) Tops Q3 EPS by 3c; Boosts FY16 Outlook

October 18, 2016 6:41 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Johnson & Johnson (NYSE: JNJ) reported Q3 EPS of $1.68, $0.03 better than the analyst estimate of $1.65. Revenue for the quarter came in at $17.8 billion versus the consensus estimate of $17.71 billion.

Xarelto revenue $529 million, versus $564 million expected.

Imbruvica revenue $349 million, estimate at $313 million.


J&J now sees FY16 adjusted EPS of $6.68 - $6.73, versus an expected range of $6.63 - $6.73 prior and compared with the current consensus of $6.69. Sales guidance was maintained.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance, Hot Earnings, Hot Guidance

Related Entities


Add Your Comment